Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA.

导出 OA

翻译打印收藏纠错

第一作者： Noriyuki,Sasaki

第一单位： Department of Surgery, Iwate Medical University School of Medicine, Yahaba, Japan.

作者： Noriyuki,Sasaki ^[1] ; Takeshi,Iwaya ^[2] ; Takehiro,Chiba ^[3] ; Masashi,Fujita ^[1] ; Zhenlin,Ju ^[2] ; Fumitaka,Endo ^[1] ; Mizunori,Yaegashi ^[4] ; Tsuyoshi,Hachiya ^[5] ; Ryo,Sugimoto ^[1] ; Tamotsu,Sugai ^[1] ; Doris R,Siwak ^[6] ; Lance A,Liotta ^[7] ; Yiling,Lu ^[7] ; Gordon B,Mills ^[8] ; Hidewaki,Nakagawa ^[9] ; Satoshi S,Nishizuka ^[8]

作者单位： Department of Surgery, Iwate Medical University School of Medicine, Yahaba, Japan. ^[1] Molecular Therapeutics Laboratory, Department of Surgery, Iwate Medical University School of Medicine, Yahaba, Japan. ^[2] Division of Biomedical Research and Development, Iwate Medical University Institute of Biomedical Sciences, Yahaba, Japan. ^[3] Laboratory for Cancer Genomics, RIKEN Center for Integrative Medical Science, Yokohama, Japan. ^[4] Department of Bioinformatics and Computational Biology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States of America. ^[5] Division of Biomedical Information Analysis, Iwate Tohoku Medical Megabank Organization, Iwate Medical University, Yahaba, Japan. ^[6] Department of Molecular Diagnostic Pathology, Iwate Medical University School of Medicine, Yahaba, Japan. ^[7] Department of Genomic Medicine, The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States of America. ^[8] Center for Applied Proteomics and Molecular Medicine, George Mason University, Fairfax, Virginia, United States of America. ^[9] Department of Cell, Development & Cancer Biology, Knight Cancer Institute, Oregon Health Science University School of Medicine, Portland, Oregon, United States of America. ^[10]